Dronabinol

How it works

Dosage & preparation

Risks & contraindications

Highlighted claims

• Dronabinol is a synthetic cannabis-based medication containing Δ9-THC that acts as a partial agonist at both cannabinoid receptor 1 and cannabinoid receptor 2. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol
• The target daily dose in the BONG trial is 20 mg dronabinol, delivered as eight 2.5 mg capsules per day. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol
• The 20 mg maximum daily dose was selected because it is the highest recommended dose for appetite stimulation in the Marinol product characteristics. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol
• Dronabinol side effects include drowsiness, dizziness, confusion, euphoria, palpitations, tachycardia, hallucination, paranoia, and elevated liver enzymes, among others. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol
• Withdrawal from dronabinol treatment may cause irritability, insomnia, nervousness, tremor, and general discomfort. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol
• The psychoactive effects of dronabinol may undermine blinding integrity in the trial. — Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark – a study protocol